Lenvatinib, toripalimab plus FOLFOX chemotherapy in hepatocellular carcinoma patients with extrahepatic metastasis: A biomolecular exploratory, phase II trial (LTSC).

MinKe He YeXing Huang Zefeng Du ZhiCheng Lai Hanyue Ouyang JingXian Shen DongSheng Wen Qi-Jiong Li Yao-Jun Zhang Wei Wei MinShan Chen Li Xu Anna Kan Ming Shi

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

FOLFOX chemotherapy in combination with lenvatinib and toripalimab showed promising antitumor activity with manageable toxicities in advanced HCC with extrahepatic metastasis. AKR1C2+ and CFHR4+ hepatocyte subtypes may be predictive biomarkers of resistance to the combination therapy.

Keyphrases

combination therapy
locally advanced
metastatic colorectal cancer
open label
rectal cancer
liver injury
chemotherapy induced
radiation therapy